Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

3.950 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
News headline image
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication. 
Via The Motley Fool
Topics Earnings Stocks
IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
Via Stocktwits
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
Via Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
Via Stocktwits
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗
Via Stocktwits
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗
A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline. 
Via The Motley Fool
News headline image
Heights Capital Walks From Archer Aviation: What It Means for Investors ↗
One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility. 
Via The Motley Fool
News headline image
Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗
One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests. 
Via The Motley Fool
News headline image
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat. 
Via Benzinga
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗
Via Stocktwits
News headline image
What's Going On With ImmunityBio Shares Tuesday? ↗
ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial. 
Via Benzinga
News headline image
IBRX Sales Soar 2,540% ↗
Via The Motley Fool
News headline image
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year. 
Via Benzinga
News headline image
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside ↗
Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest. 
Via Stocktwits
News headline image
Foot Locker And Archer Aviation Are Among Top 8 Mid-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers last week: Foot Locker, Inc. (FL), Archer Aviation Inc. (ACHR), DigitalBridge Group, Inc. (DBRG), NuScale Power Corporation (SMR), Diginex Limited (DGNX), ImmunityBio, Inc.... 
Via Benzinga
News headline image
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive ↗
ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle... 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug ↗
ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks. 
Via Benzinga
News headline image
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
News headline image
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
News headline image
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.